For the quarter ending 2025-09-30, IOBT has $39,956K in assets. $39,045K in debts. $30,664K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 30,664 | 28,131 | ||
| Prepaid expenses and other current assets | 6,167 | 10,849 | ||
| Total current assets | 36,831 | 38,980 | ||
| Restricted cash | 268 | 268 | ||
| Property and equipment, net | 544 | 603 | ||
| Right of use lease asset | 1,302 | 1,470 | ||
| Other non-current assets | 1,011 | 1,005 | ||
| Total non-current assets | 3,125 | 3,346 | ||
| Total assets | 39,956 | 42,326 | ||
| Accounts payable | 5,587 | 5,537 | ||
| Lease liability - current | 788 | 768 | ||
| Accrued expenses and other current liabilities | 11,936 | 13,592 | ||
| Total current liabilities | 18,311 | 19,897 | ||
| Lease liability - noncurrent | 667 | 868 | ||
| Term loan debt principal | 26,434 | - | ||
| Accrued paid-in-kind interest | 660 | - | ||
| Credit Facility Tranche A | 4,958 | - | ||
| Credit Facility Tranche B | 5,472 | - | ||
| Less unamortized debt issuance costs | 10,430 | - | ||
| Term loan debt, net | 16,664 | 6,720 | ||
| Common stock warrants | 3,403 | 13,249 | ||
| Total non-current liabilities | 20,734 | 20,837 | ||
| Total liabilities | 39,045 | 40,734 | ||
| Common stock, par value of 0.001 per share 300,000,000 shares authorized at september 30, 2025 and december 31, 2024 69,692,179 shares issued and outstanding as of september 30, 2025 and 65,880,914 shares issued and outstanding as of december 31, 2024 | 70 | 66 | ||
| Additional paid-in capital | 424,335 | 416,289 | ||
| Accumulated deficit | -416,329 | -407,951 | ||
| Accumulated other comprehensive loss | -7,165 | -6,812 | ||
| Total stockholders' equity | 911 | 1,592 | ||
| Total liabilities and stockholders' equity | 39,956 | 42,326 | ||
IO Biotech, Inc. (IOBT)
IO Biotech, Inc. (IOBT)